§ 01 Overview
Overview
ADNP-derived microtubule-stabilizing octapeptide. Phase 2/3 PSP trial failed primary endpoint; orphan drug designation retained for ADNP syndrome.
PSP Phase 2/3 (Boxer 2014) failed primary. Continuing development in ADNP syndrome.
§ 02 Mechanism
Mechanism of action
Davunetide (NAPVSIPQ) is the active fragment of Activity-Dependent Neuroprotective Protein (ADNP). It binds EB1/EB3 to stabilize microtubules and reduces tau hyperphosphorylation.
- 01Microtubule stabilization
- 02Tau reduction in preclinical models
- 03Orphan designation for ADNP syndrome
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 5 – 30 mg per dose (trial)
- Route
- Intranasal
- Frequency
- Daily
- Cycle
- Trial-dependent
§ 04 Evidence
Evidence & research
PSP Phase 2/3 (Boxer 2014) failed primary. Continuing development in ADNP syndrome.
FDA Status
Not FDA-approved. FDA Orphan Drug Designation for ADNP syndrome.
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
NAP of the Day: Today’s NAPs Table of horse racing tips across the UK & Ireland - Paddy Power News
NAP of the Day: Today’s NAPs Table of horse racing tips across the UK & Ireland Paddy Power News
Gravitas | People who nap frequently have 48% higher risk of developing dementia: Study - شبكة تواصل الإخبارية
Gravitas | People who nap frequently have 48% higher risk of developing dementia: Study شبكة تواصل الإخبارية
People who nap frequently have 48% higher risk of developing dementia: Study - WION
People who nap frequently have 48% higher risk of developing dementia: Study WION
Az XRP tőzsdei beáramlása 6,05 milliárd tokenre nőtt 30 nap - KuCoin
Az XRP tőzsdei beáramlása 6,05 milliárd tokenre nőtt 30 nap KuCoin
A wildlife photographer woke up from a nap under a tree with a cheetah sleeping against him - TheCoolist
A wildlife photographer woke up from a nap under a tree with a cheetah sleeping against him TheCoolist
Google Cloud's London zones takes a nap, multiple services disrupted - The Register
Google Cloud's London zones takes a nap, multiple services disrupted The Register
Driver 'took a nap' as large bee swarm settled down on car in Auckland's Birkenhead - RNZ
Driver 'took a nap' as large bee swarm settled down on car in Auckland's Birkenhead RNZ
Watch Stevie the Blind Calf's Adorable Nap Routine and His Hilarious Surprise Ending - Yahoo
Watch Stevie the Blind Calf's Adorable Nap Routine and His Hilarious Surprise Ending Yahoo
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nasal irritation
- 02Headache
Contraindications
None specified.
§ 10 Questions
Davunetide (NAP) FAQ
- What is Davunetide (NAP)?
- ADNP-derived microtubule-stabilizing octapeptide. Phase 2/3 PSP trial failed primary endpoint; orphan drug designation retained for ADNP syndrome. Davunetide (NAPVSIPQ) is the active fragment of Activity-Dependent Neuroprotective Protein (ADNP). It binds EB1/EB3 to stabilize microtubules and reduces tau hyperphosphorylation.
- What is Davunetide (NAP) used for?
- Reported uses include microtubule stabilization, tau reduction in preclinical models, and orphan designation for adnp syndrome. Evidence strength is rated Clinical — see the evidence section for detail.
- How is Davunetide (NAP) dosed?
- Commonly referenced dosing is 5 – 30 mg per dose (trial), typically daily, administered Intranasal. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of Davunetide (NAP)?
- Commonly reported side effects include nasal irritation and headache. This list is not exhaustive.
- Is Davunetide (NAP) legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Not FDA-approved. FDA Orphan Drug Designation for ADNP syndrome..
§ 11 References
Selected references
- 01
Boxer — PSP Phase 2/3
PMID: 24873720 (NCT01110720)
- 02
Gozes Transl Psychiatry 2023
PMID: 37845203